(Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7

SP-CAT-042

(Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7

US$884.00

Excluding tax and shipping fees

In stock

Description

About (Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7

(Asp28)-Glucagon (1-29) is a modified analog of human glucagon, in which asparagine at position 28 is replaced by aspartic acid to enhance stability and solubility at physiological pH. This prevents toxic aggregation seen with native glucagon in aqueous buffers while preserving biological activity, making it a valuable tool in diabetes research.

For research use only, do not use in humans!

Produced by JPT Peptide Technologies, a leader in custom peptide synthesis and diabetes reagents.

(Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7 - Specifications

Peptide sequence: H-HSQGTFTSDYSKYLDSRRAQDFVQWLMDT-OH
Amount: 0.5 mg net (50 x 10 µg) (AAA)
Purity: >95% (HPLC-MS)
Counterion: TFA
Delivery Format: Freeze-dried in plastic vial
Chemical formula: C153H224N42O50S
MW (average): 3483.78
Application(s): Diabetes research
Condition(s)/Topic(s): Diabetes
Standard Delivery Time: 2-5 days
CAS: 1037751-81-7
SMILES: N[C@@H](CC1=CNC=N1)C(N[C@@H](CO)C(N[C@@H](CCC(N)=O)C(NCC(N[C@@H]([C@@H](C)O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)O)C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CC4=CC=C(O)C=C4)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC6=CNC7=C6C=CC=C7)C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCCCN)=O)=O)=O)=O)CO)=O)=O)=O)=O)=O)=O)=O

Are you interested in other peptides or conjugation to a protein, nucleic acid or lipid? Choose your sequence, amount and purity with our Custom Peptide Synthesis services.

Why use Asp28-Glucagon instead of native Glucagon?

Native glucagon is a pancreatic 29-amino acid peptide hormone that regulates glucose homeostasis by counteracting insulin. It raises blood glucose levels by stimulating hepatic glycogenolysis and gluconeogenesis via glucagon receptor (GCGR) in response to lowered glucose levels. Currently applied only as an emergency treatment for severe hypoglycemia, glucagon is also being explored as a therapeutic target in diabetes.

However, its tendency to aggregate into toxic amyloid-like fibrils triggers apoptosis in vitro and limits its long-term applicability. Meanwhile (Asp28)-Glucagon prevents aggregation in aqueous buffers, improves solubility at physiological pH, and enhances chemical stability while preserving biological activity.

Consequently, (Asp28)-Glucagon offers a more robust and experimentally suitable alternative to native glucagon for research areas, such as diabetes and obesity.

We also offer unmodified Glucagon!

Research areas for Glucagon (Asp28), Human, CAS: 1037751-81-7:

Diabetes research: Researched for its role in glucagon receptor signaling, receptor binding, and downstream pathways regulating glucose homeostasis, insulin secretion, and pancreatic activity.

Hypoglycemia studies: Studied in cell-based and in vitro assays to examine glucagon secretion and counter-regulatory responses during insulin-induced hypoglycemia.

Obesity and weight loss research: Explored in metabolic studies analyzing energy expenditure, lipid metabolism, and appetite regulation influenced by glucagon analogs.

Energy and glucose metabolism exploration: Researched in biochemical and pharmacological experiments assessing hepatic glucose output, energy utilization, and overall metabolic control.

Hormonal and metabolic disorder research: Studied in models of endocrine dysfunction and metabolic syndrome to investigate altered glucagon and GLP-1 signaling.

Peptide aggregation and amyloid formation analysis: Explored using NMR, CD spectroscopy, and aggregation assays to assess structural stability compared to native glucagon.

Peptide formulation and drug development studies: Researched for formulation optimization, improving peptide stability, solubility, and design strategies for therapeutics targeting metabolic diseases.

Key Benefits of (Asp28)-Glucagon, CAS: 1037751-81-7:

Enhanced solubility: The Asp substitution improves peptide solubility at physiological pH for easier handling.

Reduced aggregation: Prevents amyloid fibril formation seen with native glucagon.

Preserved activity: Retains receptor affinity and biological function comparable to the native peptide.

Key Concepts

Structural and Functional Features of (Asp28)-Glucagon

(Asp28)-Glucagon differs from native human glucagon by a single amino acid substitution, in which asparagine (Asn) at position 28 is replaced with aspartic acid (Asp). This modification introduces a negatively charged carboxylate group near the C-terminal region, which alters the peptide’s electrostatic surface and hydrogen-bonding pattern. Structurally, this substitution enhances solubility and conformational stability under physiological pH by reducing hydrophobic interactions that promote fibril formation.

As a result, (Asp28)-Glucagon exhibits a lower tendency to self-associate or form amyloid-like aggregates compared to the native peptide. Despite this modification, the analog retains its native α-helical secondary structure and preserves high affinity for the glucagon receptor (GCGR), ensuring that its biological activity remains intact.

JPT’s Glucagon Peptides

Glucagon is a 29-amino acid polypeptide. Its primary sequence in humans is: NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH. Glucagon is a non-steroid peptide hormone produced in the pancreas. Its effect is opposite to that of insulin. Glucagon and insulin regulating blood glucose homeostasis making glucagon a potential target for the therapeutic treatment of diabetes. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides in all formats, scales and modifications to the global scientific community. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.

Benefits of JPT’s Peptides

All peptides are made in Germany
Bulk orders or custom peptide synthesis upon request
Provision of freeze-dried aliquots for enhanced stability
Proven track record
Need the conjugated or modified peptide? Contact us!

References

References for (Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7

References:
Read References with Specialty Peptides

Chabenne J, Chabenne MD, Zhao Y, Levy J, Smiley D, Gelfanov V, Dimarchi R. A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia. Mol Metab. 2014 Jan 22;3(3):293-300. doi: 10.1016/j.molmet.2014.01.006. PMID: 24749059; PMCID: PMC3986664.
Yang B, Gelfanov VM, Perez-Tilve D, DuBois B, Rohlfs R, Levy J, Douros JD, Finan B, Mayer JP, DiMarchi RD. Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists. J Med Chem. 2021 Apr 22;64(8):4697-4708. doi: 10.1021/acs.jmedchem.0c02069. Epub 2021 Apr 6. PMID: 33821647.

Testimonial:
Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands

Properties

Properties of (Asp28)-Glucagon (1-29), Human, CAS: 1037751-81-7

Properties	Values
Amount:	0.5 mg net (50 x 10 µg) (AAA)
Application:	Diabetes research
Category:	Diabetes Peptides
Condition / Topic:	Diabetes
Layout:	Freeze-dried in plastic vial
Organism:	Human
Protein Name:	Glucagon
Purity:	>95% (HPLC-MS)
Quantification:	Yes